Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CPT)

NCT00546910 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00546910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CPT)
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2007
Completion date
May 31, 2009
Enrollment
125 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder